Publications by authors named "Ingrid Gisbertz"
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Dig Dis Sci
June 2024
Article Synopsis
- In the LADI trial, researchers found that extending adalimumab (ADA) dosing intervals was just as effective as standard dosing for Crohn's disease patients in remission.
- The study aimed to create a prediction model to identify patients who could successfully increase their dosing intervals based on trial data.
- Results showed that 60.6% of patients successfully extended their dosing, with certain factors (like smoking and prior surgeries) making success less likely; the model's effectiveness needs further external validation before clinical use.
Article Synopsis
- The study aimed to evaluate the cost-effectiveness of lengthening adalimumab dosing intervals for patients with Crohn's disease who are in stable remission, compared to the standard two-week interval.
- A total of 174 patients participated, with results showing no significant difference in overall quality of life and total costs between the extended interval and control groups, although medication costs were lower in the extended group.
- Increased dosing intervals were deemed cost-effective if the value of a quality-adjusted life year is below €53,960, suggesting that for higher valuations, the conventional dosing remains more favorable.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
April 2023
Article Synopsis
- The LADI study investigated the effects of extending adalimumab dosing intervals in stable Crohn's disease patients compared to conventional 2-week dosing, focusing on clinical outcomes and the risk of infections.
- Patients in the intervention group increased their dosing to every 3 weeks and then possibly to every 4 weeks, while the control group maintained the 2-week schedule.
- The primary measure of effectiveness was the incidence of persistent disease flare-ups over 48 weeks, with a specific non-inferiority margin of 15% for comparing outcomes.
Background And Aims: Thioguanine is a well-tolerated and effective therapy for inflammatory bowel disease [IBD] patients. Prospective effectiveness data are needed to substantiate the role of thioguanine as a maintenance therapy for IBD.
Methods: IBD patients who previously failed azathioprine or mercaptopurine and initiated thioguanine were prospectively followed for 12 months starting when corticosteroid-free clinical remission was achieved (Harvey-Bradshaw Index [HBI] ≤ 4 or Simple Clinical Colitis Activity Index [SCCAI] ≤ 2).
Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
Trials
December 2022
Background: Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine. However, 15% of patients are intolerant to azathioprine which necessitates cessation of azathioprine or changes in therapy. In addition, not all patients achieve complete biochemical response (CR).
View Article and Find Full Text PDFESGE recommends the "pull" technique as the standard method for percutaneous endoscopic gastrostomy (PEG) placement.Strong recommendation, low quality evidence.ESGE recommends the direct percutaneous introducer ("push") technique for PEG placement in cases where the "pull" method is contraindicated, for example in severe esophageal stenosis or in patients with head and neck cancer (HNC) or esophageal cancer.
View Article and Find Full Text PDFESGE recommends considering the following indications for enteral tube insertion: (i) clinical conditions that make oral intake impossible (neurological conditions, obstructive causes); (ii) acute and/or chronic diseases that result in a catabolic state where oral intake becomes insufficient; and (iii) chronic small-bowel obstruction requiring a decompression gastrostomy.Strong recommendation, low quality evidence.ESGE recommends the use of temporary feeding tubes placed through a natural orifice (either nostril) in patients expected to require enteral nutrition (EN) for less than 4 weeks.
View Article and Find Full Text PDF